CTS-Clinical and Translational Science

Article	Citations
Precision Medicine, AI, and the Future of Personalized Health Care	390
COVID‐19 vaccine hesitancy: Race/ethnicity, trust, and fear	235
Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID‐19	223
Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID‐19, in Healthy Subjects	175
COVID‐19 and Immunological Dysregulation: Can Autoantibodies be Useful?	117
SARS‐CoV‐2 infection as a trigger of autoimmune response	95
The Potential of Low Molecular Weight Heparin to Mitigate Cytokine Storm in Severe COVID‐19 Patients: A Retrospective Cohort Study	89
Evolving Role for Pharmacotherapy in NAFLD/NASH	83
3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration	79
What Do We Know About Remdesivir Drug Interactions?	68
Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID‐19	62
Opportunities and challenges in translational science	60
Remote Monitoring in Clinical Trials During the COVID‐19 Pandemic	49
Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation	46
COVID‐19 and Venous Thromboembolism in Intensive Care or Medical Ward	45
Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial	44
Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice	44
First‐in‐human study of milvexian, an oral, direct, small molecule factor XIa inhibitor	44
Biolink Model: A universal schema for knowledge graphs in clinical, biomedical, and translational science	40
Risk of Metformin in Patients With Type 2 Diabetes With COVID‐19: A Preliminary Retrospective Report	40
Risk Assessment of Drug‐Induced Long QT Syndrome for Some COVID‐19 Repurposed Drugs	39
Approval success rates of drug candidates based on target, action, modality, application, and their combinations	39
An Evaluation of Biometric Monitoring Technologies for Vital Signs in the Era of COVID‐19	39
CYP2C19 Allele Frequencies in Over 2.2 Million Direct‐to‐Consumer Genetics Research Participants and the Potential Implication for Prescriptions in a Large Health System	37
Effect of selenium on thyroid autoimmunity and regulatory T cells in patients with Hashimoto’s thyroiditis: A prospective randomized‐controlled trial	34

Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID‐19	34
Hydroxychloroquine for Treatment of SARS‐CoV‐2 Infection? Improving Our Confidence in a Model‐Based Approach to Dose Selection	31
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo‐controlled,	31
hIL‐7‐hyFc, A Long‐Acting IL‐7, Increased Absolute Lymphocyte Count in Healthy Subjects	31
Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID‐19: An Open‐Label Randomized Controlled Pilot Study	31
Digitally Enabled, Patient‐Centric Clinical Trials: Shifting the Drug Development Paradigm	31
Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet‐induced obese and biopsy‐confirmed mouse model of NASH	30
A Single and Multiple Ascending Dose Study of Toll‐Like Receptor 7 Agonist (RO7020531) in Chinese Healthy Volunteers	30
A Strategy to Treat COVID‐19 Disease With Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study	30
Gene therapy for diabetic peripheral neuropathy: A randomized, placebo‐controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor	28
Fit‐for‐Purpose Biometric Monitoring Technologies: Leveraging the Laboratory Biomarker Experience	27
Human Induced Pluripotent Stem Cell Derived Sensory Neurons are Sensitive to the Neurotoxic Effects of Paclitaxel	27
Association Between Prescribed Ibuprofen and Severe COVID‐19 Infection: A Nationwide Register‐Based Cohort Study	27
A Phase I Study of Dinaciclib in Combination With MK‐2206 in Patients With Advanced Pancreatic Cancer	26
Effect of SLCO1B1 Polymorphisms on High‐Dose Methotrexate Clearance in Children and Young Adults With Leukemia and Lymphoblastic Lymphoma	25
The anti‐C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID‐19	25
Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)	25
Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse events	25
Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults	24
Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction	24
Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)	23
The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence	23
A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID‐19	23
Drugs used for the treatment of cerebral and disseminated infections caused by free‐living amoebae	23
Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo‐Controlled, Phase II Trial	22
Pharmacogenomics guided versus standard antidepressant treatment in a community pharmacy setting: A randomized controlled trial	22
Safety, tolerability, and pharmacokinetics of oral baicalein tablets in healthy Chinese subjects: A single‐center, randomized, double‐blind, placebo‐controlled multiple‐ascending‐dose study	22
Effect of Common Medications on the Expression of SARS‐CoV‐2 Entry Receptors in Kidney Tissue	22
First Clinical Study with AP30663 ‐ a KCa2 Channel Inhibitor in Development for Conversion of Atrial Fibrillation	22
Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19	22
Safety, tolerability, and pharmacokinetics of single‐ and multiple‐dose administration of islatravir (MK‐8591) in adults without HIV	21
Artificial intelligence in pharmacology research and practice	21
First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2	20
Population Pharmacokinetics of Remimazolam in Procedural Sedation With Nonhomogeneously Mixed Arterial and Venous Concentrations	20
Effect of difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression: A randomized, double‐blind, placebo‐controlled trial	20
Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin	20
Role for Drug Transporters in Chemotherapy‐Induced Peripheral Neuropathy	20
Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database	19
Altered vitamin A metabolism in human liver slices corresponds to fibrogenesis	18
Exocrine Pancreatic Dysfunction Increases the Risk of New‐Onset Diabetes Mellitus: Results of a Nationwide Cohort Study	18
Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF‐06826647: A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation Study	18
Antinuclear antibodies in COVID 19	18
Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD	18
Identification of BAG2 and Cathepsin D as Plasma Biomarkers for Parkinson’s Disease	18
Upadacitinib pharmacokinetics and exposure‐response analyses of efficacy and safety in psoriatic arthritis patients – Analyses of phase III clinical trials	17
Artificial intelligence in clinical and translational science: Successes, challenges and opportunities	17
Substantially Increased Plasma Coproporphyrin‐I Concentrations Associated With OATP1B1*15 Allele in Japanese General Population	17
Characterizing Pharmacogenetic Testing Among Children’s Hospitals	17
Associations of HLA genetic variants with carbamazepine‐induced cutaneous adverse drug reactions: An updated meta‐analysis	16
Metformin Preconditioning and Postconditioning to Reduce Ischemia Reperfusion Injury in an Isolated Ex Vivo Rat and Porcine Kidney Normothermic Machine Perfusion Model	16

Development and Analytical Validation of a 29 Gene Clinical Pharmacogenetic Genotyping Panel: Multi‐Ethnic Allele and Copy Number Variant Detection	16
Reimagining the peer‐review system for translational health science journals	16
DNA Methylation‐Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia	16
Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers	16
Progress toward a universal biomedical data translator	16
Dose‐dependent inactivation of airway tryptase with a novel dissociating anti‐tryptase antibody (MTPS9579A) in healthy participants: A randomized trial	15
A Dynamic Quantitative Systems Pharmacology Model of Inflammatory Bowel Disease: Part 1 – Model Framework	15
Clinical evaluation of large volume subcutaneous injection tissue effects, pain, and acceptability in healthy adults	15
Retrospective Review of Pharmacogenetic Testing at an Academic Children’s Hospital	15
GSTP1andABCB1Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel‐Based Chemotherapy in Ovarian Cancer	15
Remote FEV1 Monitoring in Asthma Patients: A Pilot Study	15
A Randomized Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Erwinia Asparaginase (JZP‐458) in Healthy Adult Volunteers	15
Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study	14
Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first‐in‐human and first‐in‐patient trials	14
Improving the Pharmacodynamics and In Vivo Activity of ENPP1‐Fc Through Protein and Glycosylation Engineering	14
The vaccine hesitancy continuum among hesitant adopters of the COVID‐19 vaccine	14
Exploratory window‐of‐opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer	14
A phase I, first‐in‐human, randomized dose‐escalation study of anti‐activated factor XII monoclonal antibody garadacimab	14
A call to action: Issuing a diversity and inclusion challenge to research organizations	14
Rivaroxaban Precision Dosing Strategy for Real‐World Atrial Fibrillation Patients	14
Insights on the Evidence of Cardiotoxicity of Hydroxychloroquine Prior and During COVID‐19 Epidemic	14
Remote Digital Monitoring for Medical Product Development	14
Autoantibodies in moderate and critical cases of COVID‐19	14
Epigenetic Changes Associated With Anthracycline‐Induced Cardiotoxicity	14
Physiologically‐based pharmacokinetic model‐based translation of OATP1B‐mediated drug–drug interactions from coproporphyrin I to probe drugs	13
Impact of the novel CYP2C:TG haplotype and CYP2B6 variants on sertraline exposure in a large patient population	13
Acceptability, Feasibility, and Utility of Integrating Pharmacogenetic Testing into a Child Psychiatry Clinic	13
A population pharmacodynamic Markov mixed‐effects model for determining remimazolam‐induced sedation when co‐administered with fentanyl in procedural sedation	13
Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia	13
Genistein‐Calcitriol Mitigates Hyperosmotic Stress‐Induced TonEBP, CFTR Dysfunction, VDR Degradation and Inflammation in Dry Eye Disease	13
Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2)	13
Advancing translational science education	13
Microphysiological systems in absorption, distribution, metabolism, and elimination sciences	13
Pharmacogenomic polygenic risk score for clopidogrel responsiveness among Caribbean Hispanics: A candidate gene approach	13
Hypomethylation of NLRP3 gene promoter discriminates glucocorticoid‐resistant from glucocorticoid‐sensitive idiopathic nephrotic syndrome patients	13
Diagnostic and prognostic capabilities of a biomarker and EMR‐based machine learning algorithm for sepsis	13
Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy	13
Evaluation of the abuse potential of difelikefalin, a selective kappa‐opioid receptor agonist, in recreational polydrug users	13
Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers	13
HLA‐associated adverse drug reactions ‐ scoping review	12
Correlation Analysis Among the Level of IL‐35, Microvessel Density, Lymphatic Vessel Density, and Prognosis in Non‐Small Cell Lung Cancer	12
A phase I evaluation of the effect of curcumin on dose‐limiting toxicity and pharmacokinetics of irinotecan in participants with solid tumors	12
Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel disease	12
Annual Bleeding Rates: Pitfalls of Clinical Trial Outcomes in Hemophilia Patients	12
Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID‐19	12
Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT‐P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study	12
SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma	12
Quantitative Clinical Pharmacology of T‐Cell Engaging Bispecifics: Current Perspectives and Opportunities	12
First‐in‐human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN‐101, a dual CD28/ICOS antagonist, in healthy adult subjects	12
Short‐ and long‐term effects of body weight loss following calorie restriction and gastric bypass on CYP3A‐activity – a non‐randomized three‐armed controlled trial	12
Evolving drug regulatory landscape in China: A clinical pharmacology perspective	12
Pharmacokinetics of bempedoic acid in patients with renal impairment	12
Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies	12
Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B‐Cell Malignancies	12
Identification of small molecules that mitigate vincristine‐induced neurotoxicity while sensitizing leukemia cells to vincristine	12
Clinical Pharmacology Studies Supporting Oligonucleotide Therapy Development: An Assessment of Therapies Approved and in Development Between 2012 and 2018	11
Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual‐acting glucokinase activator	11
Compassionate use of ruxolitinib in patients with SARS‐Cov‐2 infection not on mechanical ventilation: Short‐term effects on inflammation and ventilation	11
Perioperative Dexmedetomidine Improves Outcomes of Kidney Transplant	11
PF‐07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID‐19 patients	11
In vitro safety “clinical trial” of the cardiac liability of drug polytherapy	11
Predicting Resolvin D1 Pharmacokinetics in Humans with Physiologically‐Based Pharmacokinetic Modeling	11
Serum Metabolomic Profiles Associated With Untreated Metabolic Syndrome Patients in the Chinese Population	11
Important Pharmacogenetic Information for Drugs Prescribed During the SARS‐CoV‐2 Infection (COVID‐19)	11
The economics of moonshots: Value in rare disease drug development	11
MicroRNA‐100 Enhances Autophagy and Suppresses Migration and Invasion of Renal Cell Carcinoma Cells via Disruption of NOX4‐Dependent mTOR Pathway	11
Pharmacokinetics, bioavailability, and bioequivalence of lower‐sodium oxybate in healthy participants in two open‐label, randomized, crossover studies	11
Therapeutic Potential of Mesenchymal Stem Cells for Postmastectomy Lymphedema: A Literature Review	11
REGN1908‐1909 monoclonal antibodies block Fel d 1 in cat allergic subjects: Translational pharmacokinetics and pharmacodynamics	11
G970R‐CFTR Mutation (c.2908G>C) Results Predominantly in a Splicing Defect	11
Pharmacokinetic equivalence of CT‐P17 to high‐concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects	11
Effect of cenobamate on the single‐dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects	11
Preoperative medication use and development of postoperative delirium and cognitive dysfunction	11
Virtual screening FDA approved drugs against multiple targets of SARS‐CoV‐2	11
Pharmacokinetic equations versus Bayesian guided vancomycin monitoring: Pharmacokinetic model and model‐informed precision dosing trial simulations	10
Optimizing COVID‐19 Candidate Therapeutics: Thinking Without Borders	10
Leveraging patient‐centric sampling for clinical drug development and decentralized clinical trials: Promise to reality	10
Evaluation of moxifloxacin in canine and non‐human primate telemetry assays: Comparison of QTc interval prolongation by timepoint and concentration‐QTc analysis	10
Pediatric Pharmacokinetics and Dose Predictions: A Report of a Satellite Meeting to the 10th Juvenile Toxicity Symposium	10
Practical publication metrics for academics	10

Cardiac sodium channel inhibition by lamotrigine: In vitro characterization and clinical implications	10
Effects of vancomycin‐induced gut microbiome alteration on the pharmacodynamics of metformin in healthy male subjects	10
Systems‐based digital twins to help characterize clinical dose–response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL	10
Design and conduct considerations for studies in patients with impaired renal function	10
Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment	10
Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria	10
Effects on the Ocular Surface from Reading on Different Smartphone Screens: A Prospective Randomized Controlled Study	10
Adherence to triple‐component antihypertensive regimens is higher with single‐pill than equivalent two‐pill regimens: A randomized controlled trial	10
Clinical Evaluation of an Investigational 5 mL Wearable Injector in Healthy Human Subjects	10
Effect of Crohn’s Disease on Villous Length and CYP3A4 Expression in the Pediatric Small Intestine	10
Effects of 5‐HT₃ receptor antagonists on cisplatin‐induced kidney injury	10
Managing endothelial dysfunction in COVID‐19 with statins, beta blockers, nicorandil, and oral supplements: A pilot, double‐blind, placebo‐controlled, randomized clini	10
Estimating peptide half‐life in serum from tunable, sequence‐related physicochemical properties	9
Adverse event profiles of epidermal growth factor receptor‐tyrosine kinase inhibitors in cancer patients: A systematic review and meta‐analysis	9
Real‐world evidence of population differences in allopurinol‐related severe cutaneous adverse reactions in East Asians: A population‐based cohort study	9
Beyond the Michaelis‐Menten: Accurate Prediction of In Vivo Hepatic Clearance for Drugs With Low KM	9
Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes	9
Asia‐inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial	9
Immune‐viral dynamics modeling for SARS‐CoV‐2 drug development	9
Proton pump inhibitor use and risk of depression and anxiety in children: nationwide cohort study	9
Effect of inhaled corticosteroids on microbiome and microbial correlations in asthma over a 9‐month period	9
Clinical differences in sirolimus treatment with low target levels between children and adults with vascular malformations – A nationwide trial	9
Sarcopenia in Patients With Normal Body Mass Index Is an Independent Predictor for Postoperative Complication and Long‐Term Survival in Gastric Cancer	9
An open‐label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma	9
Pharmacometabolomics identifies candidate predictor metabolites of an L‐carnitine treatment mortality benefit in septic shock	9
Projected Utility of Pharmacogenomic Testing Among Individuals Hospitalized With COVID‐19: A Retrospective Multicenter Study in the United States	9
Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase‐Positive Non‐Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat	9
Fear and food: Anxiety‐like behavior and the susceptibility to weight loss in an activity‐based anorexia rat model	9
Assessing the impact of COVID‐19 on registered interventional clinical trials	9
Predictors of Adverse Events and Determinants of the Voriconazole Trough Concentration in Kidney Transplantation Recipients	9
Exploration for the effect of renal function and renal replacement therapy on pharmacokinetics of remdesivir and GS‐441524 in patients with COVID‐19: A limited case series	9
Optimizing moxidectin dosing for Strongyloides stercoralis infections: Insights from pharmacometric modeling	9
Predicting citation impact from altmetric attention in clinical and translational research: Do big splashes lead to ripple effects?	9
Facilitators and barriers to pediatric clinical trial recruitment and retention in rural and community settings: A scoping review of the literature	9
Persistent follicular granulosa cell senescence and apoptosis induced by methotrexate leading to oocyte dysfunction and aberrant embryo development	9
Effects of sevelamer carbonate versus calcium acetate on vascular calcification, inflammation, and endothelial dysfunction in chronic kidney disease	9
Evaluating Potential Disease‐Mediated Protein‐Drug Interactions in Patients With Moderate‐to‐Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab	9
Active Therapy with Passive Immunotherapy May Be Effective in the Fight against COVID‐19	9
Population pharmacokinetic/pharmacodynamic modeling of the psychedelic experience induced by N,N‐dimethyltryptamine – Implications for dose considerations	9
Effects of sedative psychotropic drugs combined with oxycodone on respiratory depression in the rat	9
Type‐2 airway inflammation in mild asthma patients with high blood eosinophils and high fractional exhaled nitric oxide	9
Quantitative protein expression of blood‐brain barrier transporters in the vasculature of brain metastases of patients with lung and breast cancer	9
Optimizing the Therapeutic Window of Targeted Drugs in Oncology: Potency‐Guided First‐in‐Human Studies	9
Recommended practices and ethical considerations for natural language processing‐assisted observational research: A scoping review	9
Fasting Status and Circadian Variation Must be Considered When Performing AUC‐based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients	9
A metabolomic analysis of thiol response for standard and modified N‐acetyl cysteine treatment regimens in patients with acetaminophen overdose	8
A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK‐1654 in healthy Japanese adults	8
Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T‐cellular therapy development	8
Controlled oxygenated rewarming as novel end‐ischemic therapy for cold stored liver grafts. A randomized controlled trial	8
Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan‐induced toxicity in Asian cancer patients: Meta‐analysis	8
Population pharmacokinetic and exposure‐response analyses of ivosidenib in patients with IDH1‐mutant advanced hematologic malignancies	8
Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics	8
Hydroxychloroquine for treatment of non‐hospitalized adults with COVID‐19: A meta‐analysis of individual participant data of randomized trials	8
DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T‐cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients	8
First‐in‐human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC‐2394, in healthy volunteers	8
Estimation of glomerular filtration rate for drug dosing in patients with very high or low body mass index	8
Is this the end for ranitidine? NDMA presence continues to confound	8
Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants	8
Metabolomics analysis of the serum from children with urolithiasis using UPLC‐MS	8
Pharmacogenomic‐based personalized medicine: Multistakeholder perspectives on implementational drivers and barriers in the Canadian healthcare system	8
Efficacy of personal pharmacogenomic testing as an educational tool in the pharmacy curriculum: A nonblinded, randomized controlled trial	8
Impact of Green Tea Catechin Ingestion on the Pharmacokinetics of Lisinopril in Healthy Volunteers	8
Pharmacokinetic/pharmacodynamic modeling for dose selection for the first‐in‐human trial of the activated Factor XII inhibitor garadacimab (CSL312)	8
Determination of a clinically effective evobrutinib dose: Exposure–response analyses of a phase II relapsing multiple sclerosis study	8
Genetics of drug‐induced liver injury: Current knowledge and future prospects	8
Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS‐CoV‐2	8
Translational and pharmacokinetic‐pharmacodynamic application for the clinical development of GDC‐0334, a novel TRPA1 inhibitor	8
Chloroquine and hydroxychloroquine provoke arrhythmias at concentrations higher than those clinically used to treat COVID‐19: A simulation study	8
Impact of type 2 diabetes on in vivo activities and protein expressions of cytochrome P450 in patients with obesity	8
First‐in‐human study of JNJ‐63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia	8
Potential benefit of vitamin D supplementation in people with respiratory illnesses, during the COVID‐19 pandemic	8
Performance of Plasma Adenosine as a Biomarker for Predicting Cardiovascular Risk	8
Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR‐mutant non‐small cell lung cancer	8
High intrapatient variability of tacrolimus exposure associated with poorer outcomes in liver transplantation	8
Prognostic impact of pleural effusion in patients with malignancy: A systematic review and meta‐analysis	7
Are body surface area based estimates of liver volume applicable to children with overweight or obesity? An in vivo validation study	7
Hesitant adopters: An examination of hesitancy among adults in Arkansas who have taken the COVID‐19 vaccine	7
Early M‐Protein Dynamics Predicts Progression‐Free Survival in Patients With Relapsed/Refractory Multiple Myeloma	7
Pharmacokinetics and safety of a novel influenza treatment (baloxavir marboxil) in Korean subjects compared with Japanese subjects	7
Limited sampling strategies for estimation of tacrolimus exposure in kidney transplant recipients receiving extended‐release tacrolimus preparation	7
Altered mitochondrial metabolism in peripheral blood cells from patients with inborn errors of β‐oxidation	7
A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients	7
Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers	7
Multi‐site Investigation of Genetic Determinants of Warfarin Dose Variability in Latinos	7
Reduction of Renal Preservation/Reperfusion Injury by Controlled Hyperthermia During Ex Vivo Machine Perfusion	7
A Dynamic Quantitative Systems Pharmacology Model of Inflammatory Bowel Disease: Part 2 – Application to Current Therapies in Crohn’s Disease	7
Evobrutinib, a covalent Bruton’s tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants	7
Macrophage migration inhibitory factor predicts an unfavorable outcome after transarterial chemoembolization for hepatic malignancies	7
Computational models in inflammatory bowel disease	7
Pharmacokinetics, Pharmacodynamics, and Exposure‐Response of Lanadelumab for Hereditary Angioedema	7
Risk Factors for Bleeding and Clinical Ineffectiveness Associated With Clopidogrel Therapy: A Comprehensive Meta‐Analysis	7
Prospective evaluation of high‐dose methotrexate pharmacokinetics in adult patients with lymphoma using novel determinants of kidney function	7
Pharmacogenomic landscape of Indian population using whole genomes	7
Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin	7
Atorvastatin population pharmacokinetics in a real‐life setting: Influence of genetic polymorphisms and association with clinical response	7